1. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes 
Maxwell O. Adibe, BPharm, MPharm, PhD, Cletus N. Aguwa, PharmD, Chinwe V. Ukwe, BPharm, MPharm, PhD 
Value in Health Regional Issues 
Volume 2, Issue 2, Pages (September 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Cost-effectiveness plane. NGN, Nigerian naira; QALYs, quality-adjusted life-years.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Net monetary benefit of PC and UC at different levels of willingness to pay for a QALY. NGN, Nigerian naira; PC, pharmaceutical care; QALY, quality-adjusted life-year; UC, usual care.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Univariate sensitivity analysis of cost and utility variables on incremental cost-effectiveness ratio. NGN, Nigerian naira; QALY, quality-adjusted life-year. A = QALY (±10%); B = Adjustment rate (3% and 6%); C = Total intervention-specific cost (±20%); D = Cost of antidiabetes medications (±20%); E = Cost of antihypertensives (±20%); F = Cost of antidiabetes + antihypertensives medications (±20%); G = Total cost of drugs (±20%); H = Hospital care cost (±20%); I = Auxiliary health care cost (±20%).
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness acceptability curves. NGN, Nigerian naira; QALY, quality-adjusted life-year.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions